Pharmacodynamics: Desensitization and tolerance

Last updated: November 01, 2022

Pharmacodynamics: Desensitization and tolerance

Watch later

Watch later

Introduction to pharmacology
Drug administration and dosing regimens
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Enzyme function
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Vaccinations
Anthelmintic medications
Antimalarials
Hepatitis medications
Anti-mite and louse medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Glucocorticoids
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Insulin
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Folate (Vitamin B9) deficiency

Questions

USMLE® Step 1 style questions USMLE

0 of 1 complete

USMLE® Step 2 style questions USMLE

0 of 1 complete

A 73-year-old man with no significant past medical history develops a bowel perforation and subsequently undergoes surgical repair. He develops significant hypotension while under general anesthesia. Intraoperative blood loss is minimal. A large dose of epinephrine is administered, which temporarily raises the patient's blood pressure. Several subsequent doses of epinephrine are administered and cause a much weaker response. Which of the following mechanisms is likely contributing to the decreased effects of this medication?  

Transcript

Watch video only

Pharmacodynamics refers to the mechanisms and effects of medications within the body. Or more simply, it’s what medications do to the body and how they do it.

Alright, so in order to have an effect, most medications have to reach their target cells and bind to a receptor.

Receptors are specialized proteins both on the cell membrane and inside the cell, that can bind to a ligand.

Now, that ligand could be an agonist, which is a molecule that binds and activates a receptor.

This means the receptor changes its shape or activity, and that gives rise to a signal cascade of intracellular molecules - the second messengers, which ultimately results in some change in the cell’s function.

Okay, now if we massively expose the receptors to their agonists, we will get a huge downstream signal cascade and cellular response.

But if we continuously or persistently flood that receptor with the same agonist at the same dose, what will happen, is that the ability of the agonist to produce that response will drop.

This is actually a defense mechanism, whereby cells prevent their overstimulation by agonists.

If this happens very rapidly, like within a few minutes, it’s called desensitization or tachyphylaxis.

If this happens more gradually, like over the course of days to weeks, it’s called tolerance.

Desensitization can occur with the initial dose of a medication, while tolerance typically happens with repeated doses.

Alright, so, there are several mechanisms responsible for these phenomena. First, chronic exposure to agonists cause a decrease in the number of receptors.

The decrease in the number of the receptors could result from the reduced synthesis of new receptors, also known as downregulation.

Also, chronic exposure increases the degradation of preexisting receptors through endocytosis, also known as sequestration or internalization.

This is when the cell swallows up the receptor in vesicles pinching off from the cell membrane and sends them to the lysosome for digestion.

This phenomena can be seen in chronic opioid and other drug users where the target receptors are down regulated, so a higher dose is needed to achieve the same high.

Key Takeaways

Desensitization and tolerance are two related but distinct concepts that describe changes in the body's response to a drug over time. Desensitization refers to a decrease in the response of a receptor to a drug, resulting in a reduced effect of the drug. This can occur due to a decrease in the number of receptors or a change in the way the receptors interact with the drug.

Tolerance refers to a decrease in the effectiveness of a drug over time, requiring the use of higher doses to achieve the same effect. Tolerance can occur due to several mechanisms, such as changes in the number or function of receptors, changes in the way drugs are metabolized, or changes in the way drugs are transported across the blood-brain barrier.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance" Pharmacological Reviews (2013)
  4. "Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches" International Journal of Molecular Sciences (2017)
  5. "Neurobiologic Processes in Drug Reward and Addiction" Harvard Review of Psychiatry (2004)
  6. "GPCR desensitization: Acute and prolonged phases" Cellular Signalling (2018)
  7. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)